Table 1.
Overview of studies that have investigated human lrNK cell function.
| References | Intrahepatic NK cell subset (A) | Comparison cell subset (B) | Functional difference (A) vs. (B) | Stimulation |
|---|---|---|---|---|
| Harmon et al. (16) | Hepatic CD56bright | PB CD56bright | Enhanced CD107α and reduced IFN-γ expression | MHC Class I deficient K562 target cells effector:target 5:1 for 4 h either with or without overnight rhIL-2 priming |
| Hudspeth et al. (13) | Hepatic CD56bright | PB CD56dim | Similar IFN-γresponses | 20 ng/ml rhIL-12 and 200 U/ml rhIL-2 for 18 h |
| Stegmann et al. (11) | Hepatic CXCR6+ | Hepatic CXCR6− | Lower IFN-γresponses | IL-12/IL-18 (5 ng/ml, 50 ng/ml) for 4 h |
| Aw Yeang et al. (33) | Hepatic CD49e− | Hepatic CD49e+ | Similar IFN-γ and TNF-αresponses | PMA (20 ng/ml) and ionomycin (1 mg/ml) for 6 h |
| Sun et al. (34) | Hepatic CD160+ | Hepatic CD160− | Higher basal IFN-γ | Unstimulated |
| Lunemann et al. (35) | Hepatic CXCR6+CD56bright | Hepatic CXCR6−CD56bright | Reduced IFN-γ and TNF-α | 0.221 cells at an effector:target cell ratio of 5:1 for a total of 6 h |
| Zhao et al. (36) | Hepatic CXCR6+CD16− | PB and hepatic CXCR6−CD16+ | More CD107α vs. both PB and hepatic CXCR6−CD16+ More IFN-γ vs. hepatic CXCR6−CD16+ | IL-12/IL-18 (50 ng/ml) for 6 h |